Key Drivers
- Expanding Margins
- Strong Liquidity
- Share Dilution
AIAI Summary
ISRG remains a high-quality installed-base compounder, but at a premium valuation investors should require evidence that da Vinci 5, Ion, and international expansion can sustain growth despite slower U.S. procedures and lower instrument revenue per case from Extended Use Instruments.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Expanding Margins
- •Strong Liquidity
- •Share Dilution
ISRG combines exceptional profitability, free cash flow, and debt-free liquidity with a premium valuation and dilution risks, favoring caution on entry price.
Price Behavior
Key Price Behavior Insights:
- •Strong rebound
- •Resistance approaching
- •Support critical
ISRG gained 5% last month and is nearing $397.72–$401.27 resistance; hold above $377–$383 support to sustain the rebound, while a breakout above resistance would be bullish.
Sharp rebound from the $350.16 low, rising eight of nine sessions
Sentiment & News
Key News Insights:
- •R&D Expansion
- •Ion Momentum
- •Growth Risks
Intuitive Surgical's innovation, Ion growth, and expanded EU indication support long-term upside, but slower procedures, China uncertainty, and valuation volatility remain near-term risks.
The news is cautiously positive for ISRG's long-term growth outlook, though near-term volatility may persist
Similar Companies in Healthcare
Other companies in the same sector with AI ratings